Boma Medical's ChiNext IPO Application Accepted; Ranked Fourth in China's Coronary Balloon Catheter Market in 2024

According to the Zhicheng Finance APP, on December 24, BrosMed Medical Co., Ltd. (referred to as: BrosMed Medical) IPO application for the ChiNext Board of the Shenzhen Stock Exchange has been accepted. China International Capital Corporation Limited is its sponsor institution, and it plans to raise 1.7 billion yuan.

According to the prospectus, BrosMed Medical focuses on the research and development, production, and global sales of high-performance vascular interventional medical devices. It is a leading provider of complex vascular disease interventional treatment solutions in the global industry, as well as a leading R&D and production enterprise in China in terms of production and sales volume in the field of vascular interventional balloon catheters.

In terms of product system construction, the company has formed a comprehensive product matrix covering multiple treatment scenarios, with more than 50 product series. The application fields of these products encompass key areas such as coronary intervention, peripheral intervention, neurointervention, hemodialysis access, and interventional accessories. Specifically, they include various core product lines such as general balloon catheters, functional balloon catheters, drug-coated balloon catheters, interventional guidewires and catheters, various thrombus management devices, calcification treatment devices, and energy-based therapeutic devices, fully meeting the diverse clinical needs for the interventional treatment of complex vascular diseases.

In terms of R&D and production layout, the company emphasizes global resource integration and production capacity assurance. It has currently established 5 R&D centers and laboratories worldwide to continuously drive core technology iteration and innovative product development. Additionally, it has built 4 production bases to ensure large-scale, high-quality supply of products, while setting up 3 international operation centers to provide efficient operational support and service assurance for global market expansion.

In terms of market coverage, the company's products have been successfully marketed in over 100 countries and regions worldwide, serving more than ten thousand hospitals and medical centers globally. With stable product performance, systematic treatment solutions, and professional technical support, BrosMed Medical has established a strong brand image in the global vascular interventional medical device market, gradually building up a global market presence and customer service network.

BrosMed Medical, as a leading medical technology innovation platform enterprise in the field of complex vascular interventional treatment, excels in innovation, technology, scale, and globalization. Since it began generating sales, both domestic and overseas markets have maintained a long-term stable and high-speed growth trend. From 2022 to 2024, the compound annual growth rate of revenue reached 48.98%, making it one of the companies with long-term high growth potential in the global vascular intervention industry. The company has established international operation centers in China, Europe, and the United States, and has arranged local marketing offices in multiple countries and regions, providing efficient and professional services to global customers and partners. It has built a long-term and stable marketing channel system in over 100 countries and regions worldwide, cooperating with more than 200 overseas distributors and nearly 800 domestic distributors, serving tens of thousands of hospitals and medical centers.

BrosMed Medical, a leading enterprise in the field of vascular interventional medical devices, has secured a leading position in the market with its technical advantages and scaled production capabilities in products such as balloon catheters. According to Frost & Sullivan, in 2024, BrosMed Medical ranked fourth in the Chinese Coronary Balloon Dilatation Catheter Market with a 9.6% market share, and ranked first among domestically produced brands; it also ranked fifth in the Chinese Peripheral Artery Balloon Dilatation Catheter Market with a 4.7% market share.

The use of proceeds from this fundraising has been approved by the seventh meeting of the second board of directors held on November 18, 2025, and the third extraordinary shareholders' meeting held on December 3, 2025. The company has always focused on the research, development, production, and global sales of high-performance vascular interventional medical devices, and the use of proceeds from this fundraising will be centered around its main business operations. If this stock issuance is successful, the net proceeds after deducting issuance expenses will be invested in the following projects in order of priority:

Financially, for the years 2022, 2023, 2024, and January-June 2025, the company achieved operating revenues of approximately RMB 207 million, RMB 335 million, RMB 460 million, and RMB 303 million, respectively. During the same periods, the net profits were RMB -36.0614 million, RMB 25.9914 million, RMB 76.7847 million, and RMB 35.6496 million, respectively.